Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from DocMorris ( (CH:DOCM) ).
DocMorris reported a significant increase in Rx sales by over 40% in the first half of the year, alongside a total sales growth of 10.2%. The company launched the AI-based DocMorris Assistant to enhance its digital health ecosystem, aiming to position itself as Europe’s trusted health companion. TeleClinic, part of DocMorris, saw sales surge by over 150%, becoming integral to regular care in Germany. The company’s focus remains on profitability and growth, especially in the non-Rx business, despite the discontinuation of the Zur Rose brand.
The most recent analyst rating on (CH:DOCM) stock is a Buy with a CHF10.00 price target. To see the full list of analyst forecasts on DocMorris stock, see the CH:DOCM Stock Forecast page.
More about DocMorris
DocMorris AG is a leading Swiss company specializing in online pharmacy, marketplace, and professional healthcare services, with a strong presence in Germany and other European countries. The company operates a highly automated logistics center in the Netherlands and is a prominent marketplace for health and care products in Southern Europe. DocMorris aims to create a digital health ecosystem, offering a wide range of products and services to manage health digitally.
Average Trading Volume: 544,979
Technical Sentiment Signal: Sell
Current Market Cap: CHF366.8M
See more insights into DOCM stock on TipRanks’ Stock Analysis page.